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ABSTRACT
Purpose: We previously demonstrated that converting patients from the enzymeinducers phenytoin or carbamazepine to the non-inducers levetiracetam or lamotrigine
reduces serum lipids and C-reactive protein (CRP). We sought to determine if the same
changes would occur when patients were switched to topiramate, which has shown
some evidence of enzyme induction at high doses. We also examined the effects of
drug switch on low-density lipoprotein (LDL) particle concentration.
Methods: We converted 13 patients from phenytoin or carbamazepine monotherapy to
topiramate monotherapy (most at doses of 100-150 mg/day). Fasting lipids, including
LDL particle concentration, and CRP were obtained before and ≥6 weeks after the
switch. A group of normal subjects had the same serial serologic measurements to
serve as controls.
Results: Conversion from inducers to topiramate resulted in a -35mg/dL decline in total
cholesterol (p=0.033), with significant decreases in all cholesterol fractions,
triglycerides, and LDL particle concentration (p≤0.03 for all), as well as a decrease of
over 50% in serum CRP (p<0.001). Alterations in cholesterol fractions and CRP
remained significant when compared to those seen in normal controls.
Conclusions: Changes seen when inducer-treated patients are converted to TPM
closely mimic those seen when inducer-treated patients are converted to lamotrigine or
levetiracetam. These findings provide evidence that CYP450 induction elevates CRP
and serum lipids, including LDL particles, and that these effects are reversible upon
deinduction. Low-dose TPM appears not to induce the enzymes involved in cholesterol
synthesis.
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INTRODUCTION
Antiepileptic drugs (AEDs) that induce the cytochrome P450
(CYP450) system alter metabolism in a variety of ways that may become
apparent when patients are started on or taken off these drugs. Patients
switched from the enzyme-inducing agents phenytoin (PHT) or
carbamazepine (CBZ) to the non-inducing drugs levetiracetam (LEV) or
lamotrigine (LTG) experience a sizable drop in serum lipids, along with
changes in other serologic indices of vascular risk, including C-reactive
protein (CRP)(Mintzer et al., 2009). Other studies have suggested that
patients treated with PHT or CBZ may have higher lipid levels than
controls; at least one such study measured before and after treatment and
found that CBZ produced significant elevation of lipids(Bramswig et al.,
2003; Nikolaos et al., 2004). Furthermore, the potent CYP450 inhibitor
ketoconazole has been shown to reduce cholesterol production in
experimental animals(Gibbons, 2002), and this effect is corroborated
clinically by the finding that patients taking valproate, an AED with CYP450inhibiting properties, have lower cholesterol levels than controls(Nikolaos et
al., 2004). These findings imply that serum lipids — and possibly CRP —
parallel the activity of the CYP450 enzyme system, so that treatment with a
CYP450 inducing agent increases lipids, and upon withdrawal of the drug
they return to the patient’s baseline.
A number of the older AEDs — including PHT, CBZ, phenobarbital
and primidone — are well-known to be potent CYP450 inducers, while
many of the newer-generation agents — such as LEV, LTG, or gabapentin
— clearly have no CYP450 effects. For some of the newer agents,
however, the situation with regard to CYP450 effects is less clear-cut. For
example, oxcarbazepine (OXC) has been shown to induce CYP3A4 and

3A5, leading to important drug interactions, and it also likely induces the
metabolism of vitamin D(Mintzer et al., 2006). Yet it appears not to have
effects on lipids like those of CBZ(Isojarvi et al., 1994), suggesting that it
shares some of the metabolic effects of enzyme inducing agents, but not all
of them.
Here we describe the effects on lipids and CRP when patients are
switched from either CBZ or PHT to topiramate (TPM), a newer-generation
AED that is widely used for both seizures and migraines. TPM induces at
least some CYP450 enzymes at high doses(Rosenfeld et al., 1997), but there
is no evidence of any CYP450 induction when it is used at low to moderate
doses(Doose et al., 2003). Its effects on lipids relative to those of other AEDs
have not been studied but are pertinent to the care of patients who are
chronically treated with the drug. In addition to measurements of traditional
lipid fractions, CRP, and lipoprotein(a), we also present data on changes in
low-density lipoprotein (LDL) particle concentration, as this measure, which
is distinct from the measurement of the amount of cholesterol carried by
LDL particles (LDL-C), may have independent predictive power for
myocardial infarction(Rosenson et al., 2002).

METHODS
Subjects
The study involved 13 patients from the Jefferson Comprehensive
Epilepsy Center or Thomas Jefferson University Hospital who were a)
being treated with PHT or CBZ in monotherapy for at least 1 month and b)
being crossed over to monotherapy with TPM based upon the
recommendation of the treating epileptologist at our center. Drug

conversion was undertaken due to incomplete seizure control, side effects,
or concerns about the long-term effects of enzyme-inducing AED
treatment. Of these 13 patients, one was being treated with fenofibrate
(which is not subject to CYP450 induction) and another was taking
fluvastatin and ezetimibe; the latter patient was excluded from
measurement of traditional lipid fractions. All other patients were taking no
lipid-lowering agents. As a comparator group, we utilized the same cohort
of 16 normal control subjects described in our previous report who were not
being treated with any anticonvulsant or lipid-lowering medications(Mintzer
et al., 2009). These subjects provided fasting blood samples for the same
serologic measures on two occasions approximately 10 weeks apart.

Protocol
Each subject provided two fasting blood samples: one while still on
treatment with the old (enzyme-inducing) AED, and one after switch to TPM
monotherapy. The latter sample was obtained at least 6 weeks after the
last dose of the old AED to ensure sufficient time for complete de-induction
of the CYP450 system. The schedule for conversion from the older drug to
TPM was individually determined by the patient’s treating epileptologist.
The target dose of TPM was also determined by the patient’s treating
physician based upon perceived clinical need; this was 50-75 mg twice
daily in all cases except for a single patient who was titrated up to 150 mg
twice daily. Subjects were instructed to fast at least 10 hours prior to each
blood draw, and samples were analyzed for lipid factions, lipid particle
concentrations, and Lp(a), as well as for the serum level of the AED the
patient was taking at that time.
Lipid measurements were performed by a specialty lipid laboratory
(Liposcience, Raleigh, NC). The analytical specifications are as

documented in our previous investigation(Mintzer et al., 2009). LDL-C was
measured directly rather than being calculated using the Friedwald formula.
Lipid particle concentrations were measured using a nuclear magnetic
resonance spectroscopy technique, yielding a signal which can resolve the
different classes of lipoproteins with a high degree of accuracy. Drug levels
were performed at the Thomas Jefferson University Hospital laboratory.

Statistical analysis
Data were analyzed using a general linear model when they were
normally distributed; where examination of residuals suggested nonGaussian distribution due to outliers, which was the case for total
cholesterol (TC) and high-density lipoprotein cholesterol (HDL-C), robust
MM regression was utilized instead(Yohai, 1987). Lp(a) is well-known to
have a non-normal distribution, so log transformation was used for these
data prior to calculation of the change between draw 1 and draw 2. The
mean change from draw 1 to draw 2 was calculated for each measure in
each subject, with comparison then made between the patients and the
normal subjects for each measure. In addition, all models controlled for the
baseline (draw 1) value (with slopes permitted to differ among the two
groups of subjects if those slopes were found to be significantly different).
The numbers reported for within group change from draw 1 to draw 2
reflect the predicted change in an individual measure given the average
draw 1 value for the group. Between-group comparison is based on
simultaneous testing of the difference in slopes and intercepts of the
regression on draw 1 when slopes were found to be significantly different.
Otherwise the regression lines are parallel with the same slope and
between-group comparison is the usual comparison of the intercepts. No
corrections were made for multiple comparisons since many of these

measures are dependent upon each other. Data were analyzed in SAS 9.1
(SAS Institute, Cary, NC) and S-Plus (Insightful Corporation, Seattle, WA).

RESULTS
Baseline characteristics
Of the 13 patients completing the study, 6 were switched from CBZ to
TPM and 7 were switched from PHT to TPM. Five of the CBZ-treated
patients and 2 of the PHT-treated patients were female. The mean age of
the whole cohort was 54 years (range 22 - 88). They had been treated with
CBZ or PHT for anywhere between 30 days and 35 years. In the CBZtreated patients, drug levels at baseline ranged from 5.5 to 10.4 µg /mL
(mean: 7.6). In the PHT-treated patients, drug levels ranged from 8.9 to
30.1µg /mL except for a single patient with a level of 3.3µg /dL (mean: 14.0
µg /mL). The second blood draw was always obtained at least 6 weeks
after the last dose of the enzyme-inducing AED; the total time between
draws also included a period of several weeks to titrate up TPM and then
titrate down the old drug. The time between the first and second blood
draws in these patients ranged from 76 to 301 days (mean: 169 days). The
normal comparator group (n=16), described in the previous publication
(Mintzer et al., 2009), was 50% female, with a younger mean age (39
years) than these study subjects; however, neither age nor gender was a
significant covariate for any of the study variables, so the reported results
are unadjusted for these.

Standard lipid measures

Data on standard lipid measures for patients (n=12) and normal
controls (n=16) are presented in the Table. (Note that when the same raw
data for normal subjects is analyzed together with a different drug-treated
group, the model-predicted values are slightly different; thus, the numbers
for the normal subjects differ a bit from those presented in the previous
paper, even though it is the same data.) Total cholesterol (TC) declined a
mean of 35 mg/dL in the epilepsy patients after switch to TPM (p=0.033;
Fig. 1). This decline was significantly reflected in all lipid fractions, including
non-HDL-C (-18 mg/dL, p=0.011), LDL-C (-18 mg/dL, p=0.023), serum
triglycerides (TRIG)(-54 mg/dL, p<0.001), and HDL-C (-10 mg/dL,
p=0.001). The single patient who was switched to high-dose TPM, with one
of the higher TPM levels in the study, had a decline of 37mg/dL in TC after
switch.
When the changes observed in the drug-treated patients were
compared to those seen in the normal subjects, there was a trend toward a
larger decline in TC and a strong trend toward a larger decline in non-HDLC among the patients (p=0.09 and 0.051 respectively), while the changes
LDL-C, HDL-C, and non-HDL-C were significantly greater in the patients
(p=0.019, 0.024, and 0.051 respectively).

Additional vascular risk markers
Data regarding non-traditional vascular risk markers for patients
(n=13) and controls are also presented in the Table. Lp(a) did not decline
significantly after drug switch. LDL particle concentration declined
significantly in the patients after switch to TPM (-21%, p=0.002). The
change in Lp(a) remained marginally significant when compared to the
change seen in the normal subjects (p=0.09). CRP dropped by more than

half after switch to TPM (-59%; p=0.001), a change which remained
significant in comparison to the change seen in the normal subjects
(p=0.018). The decline was highly consistent between patients (Fig. 2).

DISCUSSION
This is, to our knowledge, the first study to directly compare lipid
levels under TPM treatment to those obtained under treatment with other
AEDs. It is also the first to report CRP levels in TPM-treated patients, and
the first to report LDL particle concentration in any epilepsy or AED-treated
patients. Our findings indicate that patients switched from the enzymeinducing drugs PHT or CBZ to the newer-generation agent TPM experience
substantial declines in both CRP and serum lipids, including LDL particles.
The significance of the findings in spite of the modest sample size attests to
the robust nature of the effect.
Lipid levels in TPM-treated neurological patients have been examined
in few previous investigations, only one of which was in adults with
epilepsy; that study included only female patients(Franzoni et al., 2007;
Kocer et al., 2008; Genc et al., 2010). These studies found no change in
TC after TPM treatment; one found a small decline in HDL-C only(Genc et
al., 2010). Thus, it is unlikely that TPM itself produces a significant effect
upon serum lipids. Furthermore, the results of the present study are quite
comparable to those seen when patients are switched from inducers to
LEV or LTG(Mintzer et al., 2009), two drugs which are both structurally and
biochemically unrelated to TPM. This provides additional strong evidence in
a separate group of patients in favor of the hypothesis that CYP450-

inducing agents increase lipid levels, so that switching to non-inducing
drugs results in deinduction and a return to baseline values.
Additionally, these data, combined with those of previous studies,
suggest that TPM at the doses studied here (predominantly 100-150 mg
daily) may not affect the activity of the CYP450 system, at least with regard
to the enzymes responsible for cholesterol synthesis. This is clinically
relevant, since TPM has been found to induce the metabolism of oral
contraceptive hormones at high doses, but not at low doses(Rosenfeld et
al., 1997; Doose et al., 2003), making it unclear whether its effects on the
CYP450 system are dose-dependent, enzyme-specific, or both. It is
noteworthy that the single patient in the study who was switched to highdose TPM (300mg daily), and who had one of the higher TPM levels in the
patient cohort, nonetheless had a drop of 37mg/dL in TC, suggesting that
the drug may not affect the cholesterol synthetic pathways even at high
doses. It is possible that the CYP450-inducing effects of TPM are both
enzyme- and concentration-specific, occurring only for certain enzymes,
and even then only at certain serum levels. Targetted study of patients
taking high-dose TPM is clearly needed to establish this.
While involvement of the CYP450 system in cholesterol synthesis
and metabolism is well-established, this is not the case for the synthesis of
CRP, whose metabolic pathways remain somewhat obscure. CRP has
recently been shown to be elevated in patients with epilepsy relative to
controls(Tan et al., 2009), but our previous investigation, to our knowledge,
is the only one that has examined this phenomenon in a drug-specific
fashion(Mintzer et al., 2009). The current findings reinforce those of the
previous study, demonstrating that conversion of patients from inducers to
TPM results in sharp declines in CRP similar to those seen when patients
are switched to LTG or LEV. As with lipids, this indirectly but strongly
supports the idea that CYP450 induction increases CRP, and that CRP

levels decline after switch to a non-inducer through de-induction. It remains
unclear whether the rise in CRP prompted by enzyme-inducing agents
reflects broader upregulation of inflammatory pathways or an isolated
epiphenomenon.
This is, to our knowledge, the only study that has ever examined LDL
particle concentration in patients with epilepsy or in patients taking AEDs.
The measurement of LDL particles is likely a more accurate reflection of an
atherogenic diathesis than the standard measurement of LDL-C(El
Harchaoui et al., 2007); the latter is, in effect, a surrogate marker for the
former, which until relatively recently was not measurable in an
economically feasible manner. The analogy is sometimes made to
automotive travel, with LDL particles carrying cholesterol the way cars carry
passengers; measuring LDL-C is like measuring the number of people
traveling on a highway, when what one really wants to know is the number
of vehicles. In a similar vein, evidence suggests that LDL particle
concentration has predictive power for cardiovascular events over and
above that provided by the measurement of LDL-C and other traditional risk
factors(Rosenson et al., 2002; Cromwell and Otvos, 2004). The present
data demonstrate that there is a significant decline in LDL particle number
when patients are switched from inducers to TPM, corroborating that there
is a significant improvement in atherogenic lipid fractions following CYP450
deinduction.
One factor that is unique to TPM among available AEDs is its
proclivity to reduce body weight(Verrotti et al, 2011). Weight loss itself may
have a modest downward effect on serum lipids and CRP, so that it is
possible that some of the effects observed in the present study could be
due not just to CYP450 de-induction, but also to positive effects of TPM on
these markers. Unfortunately some of our study subjects provided blood
samples at outside laboratories because they lived too far away to return to

our center, and this precluded the implementation of body weight
measurement into our protocol. But the results obtained in the present
patients are similar to those seen in other patients who were switched to
LTG or LEV, both of which are weight-neutral drugs(Mintzer et al., 2009).
Thus, we believe it is unlikely that the weight loss effects of TPM are a
major contributor to our findings.
In sum, our results demonstrate that patients taking CBZ or PHT
experience substantial declines in multiple markers of vascular risk when
switched to TPM, similar to those engendered by switch to LEV or LTG.
There are declines in HDL-C as well, but these are likely to be
overwhelmed by the negative effects on pro-atherogenic markers (nonHDL-C, TRIG, LDL particles, CRP). Thus, patients may be at higher risk for
ischemic co-morbidities while under treatment with the former agents than
while under treatment with TPM or other newer-generation, largely noninducing drugs. Epidemiologic studies will be necessary to determine
whether these serologic changes correspond to increases in endpoint
clinical events such as myocardial infarction or stroke. Based upon our
data, there is no reason to believe that the use of low-dose TPM in
neurologic practice would increase the risk of ischemic vascular disease.
Thus, there is good reason to believe that the differences between AEDs in
serologic risk factors demonstrated here (and in previous studies) are
clinically important.
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TABLE
Table: Lipid data in patients switched from an enzyme-inducing
antiepileptic drug to topiramate

Outcome
(mg/dL except as
indicated)
Total Cholesterol
Non-HDL-C
LDL-C
HDL-C
Triglyceride
Lp(a)

†

LDL Particles†
(nmol/L)
†

C-reactive protein
(mg/L)

Change from Draw 1 p-value
(within
to Draw 2
group)
(95% CI)
-9 (-35, +17)
0.473
-35 (-66, -3)
0.033

Group

N

Draw 1 Mean
(95% CI)

Normals
Patients

16
12

203 (180, 227)
227 (201, 253)

Normals
Patients

16
12

149 (127, 170)
173 (151, 195)

-5 (-17, +6)
-18 (-31, -4)

0.011

Normals
Patients

16
12

137 (116, 158)
143 (121, 166)

-11
-18

(-24, 3)
(-34, -3)

0.023

Normals
Patients

16
12

-1
-10

(-6,+ 4)
(-16, -4)

0.001

Normals
Patients

16
12

118 (81, 155)
182 (125, 238)

-11 (-32, 11)
-54 (-78, -29)

Normals
Patients
Normals
Patients

16
13
16
12

11
(7, 18)
17
(8, 33)
1266 (1067, 1503)
1574 (1346, 1841)

-3% (-20%, +17%)
-13% (-30%, +8%)
-4% (-14%, +9%)
-21% (-31%, -9%)

Normals
Patients

16
13

1.93 (0.97, 3.82)
5.60 (2.14, 14.70)

+7% (-27%, +57%)
-59% (-73%, -37%)

54
54

(48, 61)
(45, 62)

p-value
(between
groups)
0.090

0.371
0.051

0.115

0.019

0.664
0.305
<0.001
0.713
0.196
0.539

0.024
0.518
0.557

0.002

0.090

0.717
<0.001

0.018

† Lp(a), LDL particle, and C-reactive protein data log transformed; means are geometric, with differences
expressed as percentage change of ratio (draw 2/draw 1). Between-group p-values are as compared to the
untreated subjects.
HDL-C - high-density lipoprotein cholesterol. LDL - low density lipoprotein. LDL-C - low-density lipoprotein
cholesterol. Lp(a) - lipoprotein(a).

FIGURE LEGENDS
Figure 1: Change in total cholesterol in patients switched from enzymeinducing AEDs to topiramate and in normal subjects.
Each bar shows the percent change in total serum cholesterol between the first and
second draws for a single subject, with drug-treated epilepsy patients shown in blue,
and normal subjects not taking AEDs in yellow.

Figure 2: Change in C-reactive protein in patients switched from enzymeinducing AEDs to topiramate and in normal subjects.
Each bar shows the percent change in serum C-reactive protein between the first and
second draws for a single subject, with drug-treated epilepsy patients shown in blue,
and normal subjects not taking AEDs in yellow. (Note the one outlier whose CRP
increased by 867%.)
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